Episode 20. Management of Myeloma in LMICs
Blood Cancer Talks
The Barriers to Using Lenalidomide in the Hospital Setting
With limited treatment, we do have randomized trials prior to the rough novel agents showing that transplant versus no transplant, there was clearly an overall survival benefit. So I think that still probably applies if there is limited treatment. Deratumumab as you alluded to is very expensive and many people may not be able to afford that. Definitely the results from these trials cannot be extrapolated to the LMIC setting.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
